Ascendis Pharma A/S
(NASDAQ: ASND)
|
4:45 PM UTC, 05/23/24 | |||
---|---|---|---|---|
Last: $131.31 | Change: +0.17 | %Change: +0.13% | Volume: 145,617 |
Open: | $ 131.45 | Volume: | 145,617 | |
---|---|---|---|---|
High: | $ 132.26 | Yield(%) | 0.00 | |
Low: | $ 127.78 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 7.42B | |
EPS ($) | -9.64 | Shares Out: | 56.61M |
% Price Change (last 4 weeks): | -8.41 |
---|---|
% Price Change (last 13 weeks): | -16.55 |
% Price Change (last 26 weeks): | 41.01 |
% Price Change (last 52 weeks): | 47.66 |
% Price Change (year to date): | 4.12 |
Return on Equity (%): | -866.68 |
---|---|
Return on Assets (%): | -50.17 |
Return on Invested Capital (%): | -56.61 |
Gross Profit Margin (%): | 78.07 |
---|---|
Net Profit Margin (%): | -180.51 |
Operating Profit Margin (%): | -170.79 |
50-day Moving Average: | $141.07 |
---|---|
200-day Moving Average: | $119.65 |
Avg. Daily Vol. (last 50 days): | 384,984 |
Avg. Daily Vol. (last 200 days): | 434,748 |
52-wk high: | $161.00 |
52-wk low: | $83.75 |
Bid: | $131.18 |
Ask: | $131.44 |
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
|
Ascendis Pharma A/S
Tuborg Boulevard 12 Hellerup CR 2900 Phone: 45.70.22.22.44 Fax: n/a http://www.ascendispharma.com |
Earnings (1year) ($): | -9.64 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | -2.84 |
Cash Flow ($): | -8.83 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 24.59 |
Price/Book (x): | n/a |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 2.50 |
---|---|
Current Ratio (x): | 3.56 |
LT Debt/Equity (x): | n/a |
Total Debt/Equity (x): | n/a |